Skip to main content
Premium Trial:

Request an Annual Quote

Clock Soon to Start Ticking on Myriad s 3-Year Proteome Effort

SAN FRANCISCO, Jan. 9 - Myriad Proteomics in mid-January will begin trying to fulfill its pledge to map the human proteome within three years as researchers get set to move into the company's new facility, Peter Meldrum, CEO of Myriad Genetics, said on Wednesday.

 

Move-in day, Jan. 16, is when the three-year time clock starts ticking.

 

In April, Myriad joined with Hitachi and Oracle to start Myriad Proteomics. Since that time, Myriad Proteomics has designed, built, and furnished its facility Salt Lake City and hired a 50-person staff, Meldrum said. He spoke at the 20th annual JPMorgan H&Q Healthcare Conference here, which ends on Thursday.

 

Myriad Genetics has 50 percent ownership in the proteomics venture. "They will map the human proteome and we will get free access to the data," said Meldrum.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.